The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus. This RFA will use NIH R21/R33 Phased Innovation Award and the R33 Exploratory/Developmental Phase II award mechanisms. Under this RFA, applicants can submit either a combined R21/R33 (Phased Innovation Award) application or the R33 application alone; applications for R21 support alone will not be accepted. The total project period for an application submitted in response to this RFA may not exceed the following duration: R33, 3 years; combined R21/R33 application, 4 years. In the combined application, the R21 phase cannot extend beyond 2 years. For combined R21/R33 applications, the R21 phase may not exceed $100,000 direct costs per year. This program will run in parallel with a program of identical scientific scope (RFA CA-05-007) that will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms.

• Release Date: December 17, 2003
• Letter of Intent Receipt Date(s): January 16, 2004; May 17, 2004; September 17, 2004
• Application Receipt Date(s): February 17, 2004; June 17, 2004; October 18, 2004
• Contact: Contact: Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

See full description in NIH Guide: RFA: CA-05-003